Equity
€18,600 from €555,178 in 2020
Equity fell by 97% in 5 years.
AMARLES
Lifetime
10 annual accounts with figures on one time axispeak €324,145 (2025)
€324,145▲ 5.1%
peak €221,447 (2025)
€221,447▲ 3.5%
peak €555,178 (2020)
€18,600▼ 92.0%
€499,314▲ 156%
Board2 names since 2016
2 directors and 1 other
Documentsfilings and deeds
29-06-202632 days before the deadline
2025micro format
Dividend €435,466Equity from €232,619 to €18,600Debts from €195,126 to €499,314Cash from €241,612 to €335,846
Key points
from the 2025 annual accountsTurnover
≈ €490,000 estimated
The micro format states no turnover.
Debts
€499,314 96% of the balance sheet
Suppliers 0%Taxes and wages 1%Other 99%
Liquidity
0.96 was 1.94 in 2024
Short-term debts rose from €195,126 to €499,314.
Filings
10 annual accounts since 2016
The last five annual accounts were filed 2 to 32 days before the end of the period.
Position in the sector
3.6%
Lower solvency than 91% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 537 companies had the same profile as AMARLES has now. Each dot stands for 2 companies, two years later.
95.9%
were still trading
3.4%
stopped another way
0.7%
went bankrupt
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 537 companies, not a prediction for AMARLES. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0655787702
Company renamed from DR. , ANESTHESIST to AMARLES
Issue of 186 shares · Change of role: , from manager to director · General meeting of 25-09-2023 · Gazette deed
Registered office moved from Hasselt to Diepenbeek
New registered office: Bouquetstraat 56, 3590 Diepenbeek · Previous registered office: Luikersteenweg 363/2, 3500 Hasselt · General meeting of 02-03-2020 · Gazette deed
Registered office moved from Zutendaal to Hasselt
New registered office: Luikersteenweg 363/2, 3500 Hasselt - België · Previous registered office: Linkesstraat 23, 3690 Zutendaal · General meeting of 31-03-2017 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| AMARLES Diepenbeek | €517,914 | €324,145 | 3.6% | - |
| Dr. Sannen Ilse Zonhoven | €485,094 | €303,483 | 3.8% | - |
| DR PALUMBO ANESTHESIOLOGY La Louvière | €533,256 | €334,707 | 27.4% | - |
| DEWAEL RX Gesves | €505,917 | €324,838 | 3.8% | - |
| ILADI BANCO Liège | €492,846 | €338,805 | 60.5% | - |
| DOKTER MAARTEN HEMERYCK - ANESTHESIE Ghent | €484,658 | €332,809 | 40.9% | - |
| Docteur Delcour Cardiologie Neupré | €551,372 | €332,287 | 85.5% | - |
These companies have the same main activity as AMARLES: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €485,000 and €551,000, founded between 2015 and 2016.
Official details
Source: KBO- Status
- Active since 31-05-2016Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.254.288.8093590 Diepenbeek, since 31-05-2016
- Financial year end
- 31 December
- Peppol
- Reachable since 14-12-2025
Annual accounts 2025
- €517,914▲ 21.1%
- Filing
- Filed on 29-06-2026, 32 days before the end of the filing period
Insights on AMARLES
AMARLES files the micro format. That format states no turnover. The gross margin rose from €96,337 in 2016 to €324,145 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about AMARLES
- What is the company number of AMARLES?
- The company number of AMARLES is 0655.787.702. The VAT number is the same number with BE in front: BE 0655.787.702.
- Where is AMARLES based?
- The registered office is at Bouquetstraat 56, 3590 Diepenbeek.Company details
- What does AMARLES do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of AMARLES?
- AMARLES is a private limited company (BV).
- When was AMARLES founded?
- AMARLES was founded on 31-05-2016.
- Is AMARLES still active?
- Yes, AMARLES is an active enterprise in the KBO register.
- What is the turnover of AMARLES?
- The turnover in financial year 2025 is ≈ €490,000. This figure is estimated from the gross margin of €324,145 and 30 comparable companies (NACE 86220). It probably lies between €440,000 and €680,000.Financials
- Is AMARLES profitable?
- In financial year 2025, AMARLES made a profit of €221,447.
- Where can I find the annual accounts of AMARLES?
- AMARLES filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of AMARLES due?
- AMARLES must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.